ID

775

Descrizione

CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

collegamento

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4CFBF75-6AD3-69D3-E034-080020C9C0E0

Keywords

versioni (3)
  1. 26/08/12 26/08/12 -
  2. 08/07/15 08/07/15 -
  3. 08/07/15 08/07/15 -
Caricato su

26 agosto 2012

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0 Legacy
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Breast Cancer NCT00041119 Eligibility - CALGB: 40101 PRE-STUDY ELIGIBILITY CHECKLIST - 2039130v3.0

Inglese

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

1 moduli  
Unnamed1
Descrizione

Unnamed1

CALGB Study No.
Descrizione

CALGBProtocolNumber

Tipo di dati

text

CALGB Patient ID
Descrizione

CALGBPatientID

Tipo di dati

text

Unnamed2
Descrizione

Unnamed2

Patient's Name
Descrizione

Patient'sName

Tipo di dati

text

Participating Group
Descrizione

ParticipatingGroup

Tipo di dati

text

Alias
NCI Thesaurus ObjectClass
C17005
UMLS 2011AA ObjectClass
C1257890
NCI Thesaurus Property
C25364
UMLS 2011AA Property
C0600091
Patient Hospital Number
Descrizione

PatientHospitalNumber

Tipo di dati

text

Participating Group Protocol No.
Descrizione

ParticipatingGroupProtocolNo.

Tipo di dati

text

Main Member Institution/Adjunct
Descrizione

MainMemberInstitution/Adjunct

Tipo di dati

text

Participating Group Patient No.
Descrizione

ParticipatingGroupPatientNo.

Tipo di dati

text

Unnamed3
Descrizione

Unnamed3

Histologically confirmed invasive carcinoma of the breast
Descrizione

Histologicallyconfirmedinvasivecarcinomaofthebreast

Tipo di dati

text

Undergone either modified radical mastectomy or lumpectomy
Descrizione

Undergoneeithermodifiedradicalmastectomyorlumpectomy

Tipo di dati

text

Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
Descrizione

NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy

Tipo di dati

text

No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
Descrizione

Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer

Tipo di dati

text

No involvement of dermal lymphatics on pathology
Descrizione

Noinvolvementofdermallymphaticsonpathology

Tipo di dati

text

"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
Descrizione

"High-risk"node-negativebreastcancer

Tipo di dati

text

Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
Descrizione

Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative

Tipo di dati

text

No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
Descrizione

Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy

Tipo di dati

text

Age >= 18 years
Descrizione

Age>=18years

Tipo di dati

text

CTC Performance status 0-1
Descrizione

CTCPerformancestatus0-1

Tipo di dati

text

Non-pregnant and non-nursing
Descrizione

Non-pregnantandnon-nursing

Tipo di dati

text

No active congestive heart failure nor myocardial infarction within 6 months prior to registration
Descrizione

Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration

Tipo di dati

text

Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Descrizione

Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix

Tipo di dati

text

Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
Descrizione

Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene

Tipo di dati

text

Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
Descrizione

Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.

Tipo di dati

text

Date tamoxifen started
Descrizione

Datetamoxifenstarted

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Date tamoxifen discontinued
Descrizione

Datetamoxifendiscontinued

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Meets ALL of the following laboratory criteria completed within 16 days before registration
Descrizione

MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration

Tipo di dati

text

ANC >= 1000/mcL
Descrizione

ANC>=1000/mcL

Tipo di dati

text

Date obtained (ANC)
Descrizione

Dateobtained(ANC)

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Platelets >= 100,000/mcL
Descrizione

Platelets>=100,000/mcL

Tipo di dati

text

Date obtained (Platelets)
Descrizione

Dateobtained(Platelets)

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Creatinine <= 2.0 mg/dL
Descrizione

Creatinine<=2.0mg/dL

Tipo di dati

text

Date obtained (Creatinine)
Descrizione

Dateobtained(Creatinine)

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
Descrizione

TotalBilirubin<1.5xupperlimitsofnormaloflaboratory

Tipo di dati

text

Date obtained (Total Bilirubin)
Descrizione

Dateobtained(TotalBilirubin)

Tipo di dati

date

Alias
NCI Thesaurus ValueDomain
C25164
UMLS 2011AA ValueDomain
C0011008
ULN (Total Bilirubin)
Descrizione

ULN(TotalBilirubin)

Tipo di dati

text

<= 84 days since last major breast surgery
Descrizione

<=84dayssincelastmajorbreastsurgery

Tipo di dati

text

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist
Descrizione

Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist

Ritorna all'inizio della pagina

Similar models

INSTRUCTIONS: Complete all information on this form. Do not leave any entries blank.

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Unnamed1
CALGBProtocolNumber
Item
CALGB Study No.
text
CALGBPatientID
Item
CALGB Patient ID
text
Item Group
Unnamed2
Patient'sName
Item
Patient's Name
text
ParticipatingGroup
Item
Participating Group
text
C17005 (NCI Thesaurus ObjectClass)
C1257890 (UMLS 2011AA ObjectClass)
C25364 (NCI Thesaurus Property)
C0600091 (UMLS 2011AA Property)
PatientHospitalNumber
Item
Patient Hospital Number
text
ParticipatingGroupProtocolNo.
Item
Participating Group Protocol No.
text
MainMemberInstitution/Adjunct
Item
Main Member Institution/Adjunct
text
ParticipatingGroupPatientNo.
Item
Participating Group Patient No.
text
Item Group
Unnamed3
Histologicallyconfirmedinvasivecarcinomaofthebreast
Item
Histologically confirmed invasive carcinoma of the breast
text
Undergoneeithermodifiedradicalmastectomyorlumpectomy
Item
Undergone either modified radical mastectomy or lumpectomy
text
NegativetumormarginsforinvasivecancerandDCISincaseofmastectomyorlumpectomy
Item
Negative tumor margins for invasive cancer and DCIS in case of mastectomy or lumpectomy
text
Nolocallyadvancedbreastcancer,inflammatorybreastcancerormetastaticbreastcancer
Item
No locally advanced breast cancer, inflammatory breast cancer or metastatic breast cancer
text
Noinvolvementofdermallymphaticsonpathology
Item
No involvement of dermal lymphatics on pathology
text
"High-risk"node-negativebreastcancer
Item
"High-risk" node-negative breast cancer (guidelines are ER/PgR positive primary tumor >= 1 cm in greatest diameter, or ER/PgR negative tumor of any size; physician discretion is allowed)
text
Negativesentinelnodebiopsy,and/oranaxillarydissectionwhereatleast6lymphnodesareremovedandfoundtobenegative
Item
Negative sentinel node biopsy, and/or an axillary dissection where at least 6 lymph nodes are removed and found to be negative
text
Nopreviouschemotherapyorhormonaltherapy(exceptfortamoxifenasdescribedintheprotocol)forthismalignancy
Item
No previous chemotherapy or hormonal therapy (except for tamoxifen as described in the protocol) for this malignancy
text
Age>=18years
Item
Age >= 18 years
text
CTCPerformancestatus0-1
Item
CTC Performance status 0-1
text
Non-pregnantandnon-nursing
Item
Non-pregnant and non-nursing
text
Noactivecongestiveheartfailurenormyocardialinfarctionwithin6monthspriortoregistration
Item
No active congestive heart failure nor myocardial infarction within 6 months prior to registration
text
Disease-freeofpriorinvasivemalignanciesfor>5yearsexceptforcurativelytreatedbasalcellorsquamouscellcarcinomaoftheskinorcarcinomainsituofthecervix
Item
Disease-free of prior invasive malignancies for >5 years except for curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
text
Willingtostopexogenoushormonetherapy,includingoralcontraceptives,post-menopausalhormonereplacementtherapy,andraloxifene
Item
Willing to stop exogenous hormone therapy, including oral contraceptives, post-menopausal hormone replacement therapy, and raloxifene
text
Discontinuedtamoxifenattimeofenrollmenttostudyiftamoxifenhasbeenreceivedasbreastcancerpreventiveagent,orastreatmentforthismalignancyfor<=4weeks.
Item
Discontinued tamoxifen at time of enrollment to study if tamoxifen has been received as breast cancer preventive agent, or as treatment for this malignancy for <= 4 weeks. (If latter, indicate dates below)
text
Datetamoxifenstarted
Item
Date tamoxifen started
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Datetamoxifendiscontinued
Item
Date tamoxifen discontinued
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
MeetsALLofthefollowinglaboratorycriteriacompletedwithin16daysbeforeregistration
Item
Meets ALL of the following laboratory criteria completed within 16 days before registration
text
ANC>=1000/mcL
Item
ANC >= 1000/mcL
text
Dateobtained(ANC)
Item
Date obtained (ANC)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Platelets>=100,000/mcL
Item
Platelets >= 100,000/mcL
text
Dateobtained(Platelets)
Item
Date obtained (Platelets)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
Creatinine<=2.0mg/dL
Item
Creatinine <= 2.0 mg/dL
text
Dateobtained(Creatinine)
Item
Date obtained (Creatinine)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
TotalBilirubin<1.5xupperlimitsofnormaloflaboratory
Item
Total Bilirubin < 1.5 x upper limits of normal of laboratory (mg/dL)
text
Dateobtained(TotalBilirubin)
Item
Date obtained (Total Bilirubin)
date
C25164 (NCI Thesaurus ValueDomain)
C0011008 (UMLS 2011AA ValueDomain)
ULN(TotalBilirubin)
Item
ULN (Total Bilirubin)
text
<=84dayssincelastmajorbreastsurgery
Item
<= 84 days since last major breast surgery
text
Item Group
Ccrr Module For Calgb: 40101 Pre-study Eligibility Checklist
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial